BPM821S - Biosynthetic Pathways and Molecular Biology - 2nd Opp - Jan 2025


BPM821S - Biosynthetic Pathways and Molecular Biology - 2nd Opp - Jan 2025



1 Page 1

▲back to top


nAmlBIA UnlVERSITY
< OF SCIEnCE
FacultyofHealthN, atural
ResourceasndApplied
Sciences
Schoolof NaturalandApplied
Sciences
Departmentof Biology,
Chemistryand Physics
QUALIFICATION : BACHELOR OF SCIENCE HONOURS
QUALIFICATION CODE: 08BOSC
COURSE: BIOSYNTHETIC PATHWAYS AND
MOLECULAR BIOLOGY
DATE: JANUARY 2025
DURATION: 3 HOURS
13JacksonKaujeuaStreet T: +264612072012
Private Bag13388
F: +264612079012
Windhoek
E: dbcp@nust.na
NAMIBIA
W: www.nust.na
LEVEL:8
COURSECODE: BPM821S
SESSION: 1
MARKS: 100
SECOND OPPORTUNITY/ SUPPLEMENTARY: EXAMINATION QUESTION PAPER
EXAMINER:
MODERATOR:
PROF LAMECH MWAPAGHA
DR HARRIS ONYWERA
INSTRUCTIONS:
1. Answer all questions on the separate answer sheet.
2. Please write neatly and legibly.
3. Do not use the left side margin of the exam paper. This must be allowed for the
examiner.
4. No books, notes and other additional aids are allowed.
5. Mark all answers clearly with their respective question numbers.
PERMISSIBLE MATERIALS:
1. None
This question paper consists of four (4) pages including this front page.

2 Page 2

▲back to top


Question 1
[12)
(a) The Tricarboxylic acid cycle is a source of biosynthetic precursors. Provide in a tabulated form as
shown below SIX (6) metabolic precursors and from each give ONE (1) example of an amino acid
they lead to.
(6)
Metabolic Precursors Amino Acids
1
2
3
4
5
6
(b) Briefly discuss the biosynthesis of the Fatty acids
(6)
Question 2
[16)
(a) Describe FOUR (4) ways in which emerging technologies impact the discovery and application of
cancer biomarkers
(8)
(b) What are some of the Challenges involved in cancer biomarkers Development?
(8)
Question 3
[9]
(a) Why is the activation of telomerase activity a "neoplastic" trait?
(4)
(b) Give FIVE (5) contributions of Henrietta Lacksto modern medicine
(5)
Question 4
[16)
(a) Describe the two pathways utilized by the body for the excretion of compounds once they
have entered the bloodstream
(8)
(b) Give FOUR (4) reasons as to why the knowledge of mechanism of action of drugs is
important
(8)
Biosynthetic Pathways and Molecular Biology (BPM821S) 2nd Opportunity January 2025
2

3 Page 3

▲back to top


Question 5
[16)
(a) What is signal amplification in cell signaling pathways, and why is it important?
(6)
(b) Briefly describe some of the specific roles of ERK,JNK, and p38 in cell division
(10)
Question 6
[14)
(a) The signalling pathway below is responsible for multiple processes that operate during both
development and adult life.
Stimulatory agonlsts
.e,
Adenylyl
cyclase
i Cholera
p °s GDP
G~P
,
_,,:f },;_..,_,_______<I@¥
al
i
toxin 'B---~T~ ---···W·· '-0-----··-··· @GTP
~---Cyclic
Soluble adenylyl cyclase¼}
AMP --~
6'AMP
.---i-- ------ 1--~--Gr .
® 0 P.I,,~- ,._ Rap1 ,._
·-·---@________1_11
::::::::::_--------G...
f'Vh
-----/---- •• ,, ____________/7_\\__ -------------- ••
DAG
Cyclic~
lnsP 3
r.<<i6 J±f/'
bT
/ I I • ,._ "'-..
I \\ ''\\'-
•-... 'd::L..._
p
~- -----------.-.-
f:"\\ Q'Q._ ---.-.-..-..._.._._•_P
GMP
cJ ,/ cGMP PDE
t"f'
d c3 S'GMP
CREB
-~ '-._
ca2+ ···--.
p
p AYR
F-2,6-P2
phosphatase
lipase
I. Name the effectors;
(3)
II. State SIX (6) signalling functions of the pathway
(6)
Biosynthetic Pathways and Molecular Biology (BPM821S) 2nd Opportunity January 2025
3

4 Page 4

▲back to top


(b) Using the figure below explain the activation of the G2/M checkpoint following DNA
damage
(5)
Question 7
[17)
(a) Briefly describe the stages of apoptosis.
(5)
(b) The figure below shows two pathways utilised during the process of apoptosis. Name the
pathways and give a detailed description on how the key players enable apoptosis.
(12)
Apoptosis stimuli
I
! ' I
' ' pro-Caspase 8,10
I
t-Bid
t CC)'_ Active caspase 8 _.Bid
'/
+ I Cytochrome c j
I
f-- Bcl-2
IAifl
I nuclease G j
I HrtA2/0mi j
Smac/Dla"l jApar1j
tl '' 1 Caspase 3,7
Caspase 9
T
I llAPs
Apoptotic changes
Apoptotic changes
THE END
Biosynthetic Pathways and Molecular Biology (BPM821S) 2nd Opportunity January 2025
4